Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)
Henan Cancer Hospital
Henan Cancer Hospital
Hebei Medical University Fourth Hospital
Sichuan University
Guangzhou University of Traditional Chinese Medicine
Eye & ENT Hospital of Fudan University
Shanghai Simnova Biotechnology Co.,Ltd.
The First Hospital of Jilin University
Centre Hospitalier Universitaire de Besancon
Alliance for Clinical Trials in Oncology
University Hospital Ostrava
Radiotherapy Oncology Centre "Santa Maria" Hospital
Jiangsu Cancer Institute & Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Fudan University
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Peking Union Medical College Hospital
Fudan University
Ruijin Hospital
Henan Cancer Hospital
Kyungpook National University Hospital
Fondazione IRCCS Policlinico San Matteo di Pavia
Henan Cancer Hospital
Maria Sklodowska-Curie National Research Institute of Oncology
Guangzhou Gloria Biosciences Co., Ltd.
Zhejiang University
Zhongnan Hospital
Institut Paoli-Calmettes
Seoul National University Hospital
The First Hospital of Jilin University
Salah Azaïz Cancer Institute
Universitätsklinikum Hamburg-Eppendorf
Tongji University
Yixing People's Hospital
Tianjin Medical University Cancer Institute and Hospital
Institut fuer Frauengesundheit
Xijing Hospital
Shanghai Pulmonary Hospital, Shanghai, China
Yantai Yuhuangding Hospital
Yantai Yuhuangding Hospital
National Cancer Institute, Naples
Instituto do Cancer do Estado de São Paulo
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Shandong Cancer Hospital and Institute
University of California, San Diego
Sun Yat-sen University
Sykehuset i Vestfold HF
Peking Union Medical College Hospital
Sun Yat-sen University
Shanghai Chest Hospital